Skip to main content

Table 1 Clinical findings and treatments of 27 colorectal T/NK cell lymphoma patients

From: Endoscopic and clinicopathological characteristics of colorectal T/NK cell lymphoma

Clinical subtype MEITL ATLL Other group Total
No. of cases 9 (33%) 11 (41%) 7 (26%) 27
Median age (range), y 63 (47–84) 64 (50–74) 54 (43–69) 60 (43–84)
Male: female 6:3 7:4 6:1 19:8
Past history of UC 1 (11%) 0 1 (14%) 2 (7%)
Chronic diarrhea 5 (56%) 4 (36%) 2 (29%) 11 (41%)
Abdominal pain 4 (44%) 3 (27%) 4 (57%) 11 (41%)
Weight loss 4 (44%) 2 (18%) 0 6 (22%)
Fever 0 2 (18%) 2 (29%) 4 (15%)
Total protein (g/dl) 5.7 (4–6.6) 6.3 (5.4–7.2) 7.5 (5.9–8.4) 6.5 (4–8.4)
Albumin (g/dl) 3.1 (2.1–3.8) 3.4 (2.6–4) 3.9 (2.7–4.4) 3.5 (2.1–4.4)
LDH (U/l) 191 (112–288)* 785 (262–2192)* 184 (123–244) 387 (112–2192)
sIL-2R (U/ml) 1815 (587–4410)* 51,643 (3501–154,246)* 10,993 (1330–25,818) 21,484 (587–154,246)
Leukemic change 2 (22%)** 6/8 (75%)** 1 (14%) 9/21 (43%)
Clinical stage I 2 (22%) 0 2 (29%) 4 (15%)
 II (II1, II2, IIE) 3 (33%) 1 (9%) 2 (29%) 6 (22%)
  II1 1 (11%) 0 1 (14%) 2 (7%)
  II2 1 (11%) 0 0 1 (4%)
  IIE 1 (11%) 1 (9%) 1 (14%) 3 (11%)
IV 4 (44%)** 10 (91%)** 3 (42%) 17 (63%)
Surgery 1 (11%) 0 2 (29%) 3 (11%)
Surgery and chemotherapy 3 (33%) 1 (9%) 0 4 (15%)
Chemotherapy 2 (22%)** 9 (82%)** 3 (42%) 14 (52%)
Chemotherapy and SCT 2 (22%) 1 (9%) 0 3 (11%)
No treatment 1 (11%) 0 2 (29%) 3 (11%)
  1. * P < 0.01; ** P < 0.05; UC Ulcerative colitis; LDH Lactate dehydrogenase; sIL-2R Soluble interleukin-2 receptor
  2. SCT, stem cell transplantation
\